Ross J F, Chaudhuri P K, Ratnam M
Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo 43699-0008.
Cancer. 1994 May 1;73(9):2432-43. doi: 10.1002/1097-0142(19940501)73:9<2432::aid-cncr2820730929>3.0.co;2-s.
Despite significant differences in ligand binding between the two known isoforms of the human membrane folate receptor (FR), designated herein as FR-beta (placenta) and FR-alpha (placenta, KB cells), little is known about their tissue specificities, and there is no report on the relative expression of FR-beta in any tissue other than in placenta.
The mRNA for each FR isoform in a wide variety of normal fetal and adult tissue explants, primary normal cell cultures, malignant tumor explants, and established tumor cell lines was estimated by a polymerase chain reaction assay. Total receptor levels were estimated by a [3H] folic acid binding assay.
Both the FR isoforms were expressed in fetal as well as adult tissues. Normal tissues generally expressed low to moderate amounts of FR-beta. FR-alpha alone was expressed in normal epithelial cells and was frequently strikingly elevated in a variety of carcinomas, with the exception of squamous cell carcinomas of the head and neck. In contrast, a variety of malignant tissues of nonepithelial origin generally expressed elevated levels of FR-beta alone. Established tumor cell lines expressed FR-alpha virtually alone and did not reflect FR expression patterns in vivo. KB cells and JEG-3 cells grown at low folate concentrations further up-regulated FR-alpha but not FR-beta.
Although FR-beta is the more common isoform, FR-alpha and FR-beta are differentially regulated in normal tissues, carcinomas, nonepithelial malignancies, and immortalized cells or in response to changes in extracellular folate concentrations. The tissue specificity of FR isoforms and their elevation in malignant tissues may be a significant factor in FR-mediated folate uptake, in tissue responsiveness to promising novel antifolates, and in FR-related immunodiagnosis/immunotherapy.
尽管人膜叶酸受体(FR)的两种已知异构体(本文中命名为FR-β(胎盘型)和FR-α(胎盘型、KB细胞型))在配体结合方面存在显著差异,但对它们的组织特异性了解甚少,且除胎盘外,尚无关于任何其他组织中FR-β相对表达情况的报道。
通过聚合酶链反应测定法评估多种正常胎儿和成人组织外植体、原代正常细胞培养物、恶性肿瘤外植体及已建立的肿瘤细胞系中各FR异构体的mRNA。通过[3H]叶酸结合测定法评估总受体水平。
两种FR异构体均在胎儿及成人组织中表达。正常组织通常表达低至中等量的FR-β。单独的FR-α在正常上皮细胞中表达,且在多种癌中常显著升高,但头颈部鳞状细胞癌除外。相反,多种非上皮来源的恶性组织通常仅表达升高水平的FR-β。已建立的肿瘤细胞系几乎仅表达FR-α,不能反映体内FR的表达模式。在低叶酸浓度下培养的KB细胞和JEG-3细胞进一步上调FR-α,但不上调FR-β。
尽管FR-β是更常见的异构体,但FR-α和FR-β在正常组织、癌、非上皮恶性肿瘤、永生化细胞中或对细胞外叶酸浓度变化的反应中受到不同调节。FR异构体的组织特异性及其在恶性组织中的升高可能是FR介导的叶酸摄取、组织对有前景的新型抗叶酸药物的反应以及FR相关免疫诊断/免疫治疗中的一个重要因素。